From Formulary Watch:
FDA has approved lenvatinib (Lenvima, Eisai Inc.) in combination with everolimus for the treatment of advanced renal cell carcinoma. With its newest FDA approval, Lenvima is now indicated, in combination with everolimus, for the treatment of patients with advanced RCC who were previously treated with an anti-angiogenic therapy. Everolimus works by inhibiting the mammalian target of rapamycin (mTOR), which is associated with a pathway shown to be dysregulated in several cancers resulting in tumor cell growth and proliferation.
